دورية أكاديمية
أعرض في EDS

New imidazole-2-thiones linked to acenaphythylenone as dual DNA intercalators and topoisomerase II inhibitors: structural optimization, docking, and apoptosis studies.

التفاصيل البيبلوغرافية
العنوان: New imidazole-2-thiones linked to acenaphythylenone as dual DNA intercalators and topoisomerase II inhibitors: structural optimization, docking, and apoptosis studies.
المؤلفون: Mohamed AH; Chemistry Department, Faculty of Science, Minia University, El-Minia, Egypt., Alshammari MB; Chemistry Department, College of Sciences and Humanities, Prince Sattam Bin Abdulaziz University, Al-Kharij, Saudi Arabia., Aly AA; Chemistry Department, Faculty of Science, Minia University, El-Minia, Egypt., Sadek KU; Chemistry Department, Faculty of Science, Minia University, El-Minia, Egypt., Ahmad A; Chemistry Department, College of Sciences and Humanities, Prince Sattam Bin Abdulaziz University, Al-Kharij, Saudi Arabia., Aziz EA; Chemistry Department, Faculty of Science, Minia University, El-Minia, Egypt., El-Yazbi AF; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt., El-Agroudy EJ; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt., Abdelaziz ME; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
المصدر: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2024 Dec; Vol. 39 (1), pp. 2311818. Date of Electronic Publication: 2024 Mar 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basingstoke, UK : Taylor & Francis, c2002-
مواضيع طبية MeSH: Topoisomerase II Inhibitors*/pharmacology , Topoisomerase II Inhibitors*/chemistry , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry, Structure-Activity Relationship ; Intercalating Agents/pharmacology ; Thiones/pharmacology ; Cell Line, Tumor ; Imidazoles/pharmacology ; DNA ; Apoptosis ; Molecular Docking Simulation ; DNA Topoisomerases, Type II/metabolism ; Cell Proliferation
مستخلص: In this article, a new series of 2-((3,5-disubstituted-2-thioxo-imidazol-1-yl)imino)acenaphthylen-1(2 H )-ones were synthesized. Imidazole-2-thione with acenaphthylen-one gave a hybrid scaffold that integrated key structural elements essential for DNA damage via direct DNA intercalation and inhibition of the topoisomerase II enzyme. All the synthesized compounds were screened to detect their DNA damage using a terbium fluorescent probe. Results demonstrated that 4-phenyl-imidazoles 5b and 5e in addition to 4-(4-chlorophenyl)imidazoles 5h and 5j would induce detectable potent damage in ctDNA. The four most potent compounds as DNA intercalators were further evaluated for their antiproliferative activity against HepG2, MCF-7 and HCT-116 utilizing the MTT assay. The highest anticancer activity was recorded with compounds 5b and 5h against the breast cancer cell line MCF-7 which were 1.5- and 3- folds more active than doxorubicin , respectively. Therefore, imidazole-2-thione tethered acenaphthylenone derivatives can be considered as promising scaffold for the development of effective dual DNA intercalators and topoisomerase II inhibitors.
References: J Immunol Methods. 1983 Dec 16;65(1-2):55-63. (PMID: 6606682)
Anal Chim Acta. 2017 Nov 22;994:92-99. (PMID: 29126473)
Bioorg Med Chem Lett. 2001 Jan 8;11(1):67-9. (PMID: 11140736)
Genes (Basel). 2019 Oct 30;10(11):. (PMID: 31671531)
J Med Chem. 2007 Nov 15;50(23):5727-34. (PMID: 17941623)
Eur J Med Chem. 2019 Mar 15;166:267-280. (PMID: 30721822)
J Med Chem. 2010 Apr 8;53(7):2719-40. (PMID: 20131845)
Curr Med Chem. 2020;27(1):154-169. (PMID: 30569842)
Eur J Med Chem. 2018 Aug 5;156:563-579. (PMID: 30025350)
Arch Pharm (Weinheim). 2020 Nov;353(11):e2000121. (PMID: 32757353)
Int J Biol Macromol. 2023 Jan 31;226:473-484. (PMID: 36495993)
Anal Chim Acta. 2012 May 13;726:44-9. (PMID: 22541012)
J Med Chem. 2002 Jun 6;45(12):2615-23. (PMID: 12036371)
Eur J Med Chem. 2023 Mar 5;249:115116. (PMID: 36689894)
Eur J Pharm Sci. 2023 Jan 1;180:106323. (PMID: 36336277)
J Nat Prod. 2003 Aug;66(8):1101-3. (PMID: 12932133)
Sci Rep. 2016 Apr 12;6:24049. (PMID: 27068577)
Toxicol Rep. 2019 Nov 06;6:1176-1181. (PMID: 31763181)
Molecules. 2019 Aug 23;24(17):. (PMID: 31450781)
Bioorg Chem. 2020 Jul;100:103845. (PMID: 32344183)
Bioorg Chem. 2020 Mar;96:103631. (PMID: 32036164)
Acta Crystallogr Sect E Struct Rep Online. 2014 Oct 24;70(Pt 11):415-7. (PMID: 25484761)
Drug Des Devel Ther. 2021 Jul 29;15:3289-3312. (PMID: 34354342)
Eur J Med Chem. 2022 Dec 5;243:114706. (PMID: 36063665)
Front Chem. 2022 Dec 12;10:1076383. (PMID: 36578355)
Sci Rep. 2017 Mar 03;7:42717. (PMID: 28256516)
J Enzyme Inhib Med Chem. 2023 Dec;38(1):118-137. (PMID: 36305290)
J Med Chem. 2011 Jul 28;54(14):5013-30. (PMID: 21644529)
Anal Biochem. 2022 Aug 15;651:114700. (PMID: 35500656)
J Clin Pharmacol. 2008 Jun;48(6):662-70. (PMID: 18378963)
Eur J Med Chem. 2011 Sep;46(9):3909-16. (PMID: 21684048)
Eur J Med Chem. 2022 Jul 5;237:114376. (PMID: 35462164)
Pharmacol Rev. 2004 Jun;56(2):185-229. (PMID: 15169927)
Fitoterapia. 2008 Dec;79(7-8):598-601. (PMID: 18664377)
Nat Protoc. 2006;1(3):1458-61. (PMID: 17406435)
Drug Metab Rev. 2002 Feb-May;34(1-2):17-35. (PMID: 11996009)
ChemMedChem. 2016 Jun 6;11(11):1117-21. (PMID: 27218427)
Eur J Med Chem. 2023 Apr 5;252:115303. (PMID: 36996717)
Bioorg Chem. 2023 Jul;136:106548. (PMID: 37094479)
Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):379-93. (PMID: 24392841)
Bioorg Chem. 2020 Dec;105:104393. (PMID: 33120322)
J Chem Inf Model. 2007 Nov-Dec;47(6):2140-8. (PMID: 17985865)
J Enzyme Inhib Med Chem. 2022 Dec;37(1):299-314. (PMID: 34894955)
PLoS One. 2023 Jan 30;18(1):e0274081. (PMID: 36716311)
J Med Chem. 1991 Jul;34(7):2165-8. (PMID: 2066990)
Molecules. 2021 Aug 04;26(16):. (PMID: 34443307)
Molecules. 2021 Jul 11;26(14):. (PMID: 34299488)
Drug Discov Today. 2008 May;13(9-10):379-93. (PMID: 18468555)
J Inorg Biochem. 1997 Apr;66(1):7-17. (PMID: 9076969)
J Chem Inf Model. 2009 Feb;49(2):444-60. (PMID: 19434845)
فهرسة مساهمة: Keywords: DNA intercalators; New imidazole-2-thiones; doxorubicin; dual anticancer activity; topoisomerase II inhibitor
المشرفين على المادة: 0 (Topoisomerase II Inhibitors)
7GBN705NH1 (imidazole)
0 (Intercalating Agents)
0 (Thiones)
0 (Antineoplastic Agents)
0 (Imidazoles)
9007-49-2 (DNA)
EC 5.99.1.3 (DNA Topoisomerases, Type II)
تواريخ الأحداث: Date Created: 20240315 Date Completed: 20240318 Latest Revision: 20240320
رمز التحديث: 20240320
مُعرف محوري في PubMed: PMC10946275
DOI: 10.1080/14756366.2024.2311818
PMID: 38488131
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-6374
DOI:10.1080/14756366.2024.2311818